Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 18/20 | 0.57 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20006439 | 0.84 | CRACR2A (0.57) | CRACR2AORAI1KDM4EALDH1A1HPGD | |
| SCHEMBL20006307 | 0.81 | CRACR2A (0.66) | CRACR2AORAI1 | |
| SCHEMBL31293507 | 0.81 | CRACR2A (0.54) | CRACR2AORAI1KDM4EALDH1A1HPGD | |
| SCHEMBL1667944 | 0.81 | CRACR2A (0.56) | CRACR2AORAI1KDM4EALDH1A1HPGD | |
| SCHEMBL1668011 | 0.80 | CRACR2A (0.70) | CRACR2AORAI1 | |
| SCHEMBL1882594 | 0.79 | CRACR2A (0.55) | CRACR2AORAI1ALDH1A1 | |
| SCHEMBL14887733 | 0.78 | KDM4E (0.42) | CRACR2AORAI1KDM4EALDH1A1HPGD | |
| SCHEMBL29864035 | 0.78 | KDM4E (0.42) | CRACR2AORAI1KDM4EALDH1A1HPGD | |
| SCHEMBL28830089 | 0.75 | CRACR2A (0.51) | CRACR2AORAI1KDM4EALDH1A1HPGD | |
| SCHEMBL1670437 | 0.73 | CRACR2A (0.81) | CRACR2AORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2020-06-02 | — | — | US | disclosed |
| CN-110627724-A | Pyrazole derivative calcium release-activated calcium channel modulators and methods of treating non-small cell lung cancer | 理森制药股份公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2019-08-15 | — | — | US | disclosed |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2019-04-02 | — | — | US | disclosed |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2019-01-08 | — | — | US | disclosed |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2018-08-09 | — | — | US | disclosed |
| EP-2509955-B1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-9944631-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-17 | — | — | US | disclosed |
| EP-2509974-B1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-02 | — | — | US | disclosed |
| US-9758514-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-12 | — | — | US | disclosed |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2015-10-15 | — | — | US | disclosed |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8993612-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8921364-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | Rhizen Phamaceuticals SA (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8377970-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-19 | — | — | US | disclosed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | disclosed |
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885KDM4E 3486/4885 |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | CRACR2A 55/4885ORAI1 1/4885KDM4E 3583/4885 |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885KDM4E 3486/4885 |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | CRACR2A 53/4885ORAI1 1/4885KDM4E 3196/4885 |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885KDM4E 3486/4885 |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885KDM4E 3486/4885 |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | CRACR2A 53/4885ORAI1 1/4885KDM4E 3196/4885 |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885KDM4E 3486/4885 |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | CRACR2A 53/4885ORAI1 1/4885KDM4E 3196/4885 |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885KDM4E 3486/4885 |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | CRACR2A 55/4885ORAI1 1/4885KDM4E 3583/4885 |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | ORAI1, CACNA1E, CACNB2 | CRACR2A 55/4885ORAI1 1/4885KDM4E 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.